OTCMKTS:ATBPF Antibe Therapeutics (ATBPF) Stock Price, News & Analysis $0.22 0.00 (0.00%) As of 10/26/2026 Add Compare Share Share Stock Analysis Stock AnalysisChart About Antibe Therapeutics Stock (OTCMKTS:ATBPF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Antibe Therapeutics alerts:Sign Up Key Stats Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.11▼$0.89VolumeN/AAverage Volume27,352 shsMarket Capitalization$11.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Antibe Therapeutics Inc. is a Canadian biotechnology company that has focused on developing therapies for pain and inflammation. Its research centers on hydrogen sulfide-releasing medicines designed to preserve the pain-relieving and anti-inflammatory benefits of nonsteroidal anti-inflammatory drugs while potentially reducing gastrointestinal damage and other safety concerns associated with conventional NSAIDs. The company’s lead investigational product has been ATB-346, an orally administered, hydrogen sulfide-releasing derivative of naproxen. Antibe has evaluated the compound as a potential treatment for conditions involving acute and chronic pain, including osteoarthritis. The product remains investigational and is not an approved commercial medicine. Based in Canada, Antibe has historically advanced its programs through preclinical research and clinical development activities. Publicly available information about the company’s current operations, leadership and commercial presence is limited, and its development status may have changed following funding and clinical-development challenges.AI Generated. May Contain Errors. Read More Receive ATBPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATBPF Stock News HeadlinesAPLIF Appili Therapeutics Inc.August 23, 2024 | seekingalpha.comANTIBE THERAPEUTICS INC (ATBPF) stock forecast and price targetJuly 19, 2024 | finance.yahoo.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)Antibe Reports Q3 2024 Interim Financial and Operating ResultsFebruary 14, 2024 | finance.yahoo.comAntibe Therapeutics reports Q2 resultsNovember 13, 2023 | msn.comAntibe Reports PK Results of First Clinical Study of Otenaproxesul’s New FormulationNovember 9, 2023 | finance.yahoo.comIs Antibe Therapeutics (TSE:ATE) In A Good Position To Deliver On Growth Plans?October 20, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul’s New FormulationOctober 18, 2023 | finance.yahoo.comSee More Headlines ATBPF Stock Analysis - Frequently Asked Questions How have ATBPF shares performed this year? Antibe Therapeutics' stock was trading at $0.2156 at the start of the year. Since then, ATBPF stock has increased by 0.0% and is now trading at $0.2156. How were Antibe Therapeutics' earnings last quarter? Antibe Therapeutics Inc. (OTCMKTS:ATBPF) released its earnings results on Monday, November, 13th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.02. How do I buy shares of Antibe Therapeutics? Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Antibe Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antibe Therapeutics investors own include Aurora Cannabis (ACB), GoHealth (GOCO), Immunic (IMUX), 9 Meters Biopharma (NMTR), Alibaba Group (BABA), Rithm Capital (RITM) and Block (XYZ). Company Calendar Last Earnings11/13/2023Today10/27/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ATBPF CIKN/A Webwww.antibethera.com Phone(416) 922-3460FaxN/AEmployees11Year Founded2009Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-56.48% Return on Assets-29.07% Debt Debt-to-Equity RatioN/A Current Ratio10.06 Quick Ratio10.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book0.37Miscellaneous Outstanding Shares52,981,000Free Float48,238,000Market Cap$11.42 million OptionableNot Optionable Beta0.51 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (OTCMKTS:ATBPF) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYesterday's deadline changed everythingIn June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
